Key Takeaways
- Biosort raised more than $10 million from aquaculture and technology investors
- Investors include Grieg Kapital, Hatch Blue, IVC, Farvatn, and Futurum Ventures
- Funding supports final development and commercialization of its lice control system
- Technology enables early-stage lice removal and individual salmon tracking
- Company aims to reduce well-boat treatments and improve fish welfare
Biosort Raises $10 Million to Advance Commercial Launch
Biosort has secured more than NOK 100 million (approximately $10 million) from a consortium of aquaculture and technology investors to bring its individual-based lice control system to market. Investors participating in the round include Grieg Kapital, Hatch Blue, IVC, Farvatn, Futurum Ventures, along with existing shareholders.
The capital will support the final development phase and commercial rollout of Biosort’s next-generation lice control technology. The system is designed to remove sea lice at an early stage, aiming to prevent population growth and reduce the need for full-pen well-boat treatments.
Geir Stang Hauge, CEO of Biosort, said: “This funding takes us from development into commercial sales. Our focus is simple: continuous lice removal to suppress lice development and greatly reduce needs for well-boat treatments. The goal is improved welfare, lower mortality, better biological control, and ultimately making fish thrive.”
Biosort Technology Focus: Early Lice Removal and Individual Fish Tracking
Founded in 2010, Biosort has developed machine vision, artificial intelligence, and FishID technology capable of identifying and tracking individual salmon. The lice control system integrates early lice removal with individual fish data, aiming to enhance monitoring and operational precision in aquaculture.
Sea lice remain one of the primary biological challenges in salmon farming, affecting fish health, mortality rates, and production efficiency.
Stian Grieg, Investment Manager at Grieg Kapital, commented: “We have followed Biosort for several years and are impressed by the team and their technology. Sea lice remain one of the greatest challenges in salmon farming, and Biosort’s approach has the potential to improve both lice management and fish health. We are excited to support the company as it moves into commercialization.”
Investor Backing Reflects Focus on Fish Health Innovation
The investor consortium includes Hatch Blue through its Blue Revolution Fund, which targets next-generation aquaculture solutions.
Carsten Krome, Managing Partner at Hatch Blue, stated: “There is a clear shift in the salmon industry toward stronger focus on fish health and greater adoption of new technology. Through Blue Revolution Fund, we invest in next-generation aquaculture solutions that improve health and sustainability. Together with a strong and experienced investor consortium, we believe Biosort is well positioned to contribute to the next phase of salmon farming.”
With more than $10 million in new funding secured, Biosort is transitioning from development to commercialization, positioning its individual-based lice control system as part of broader efforts to improve fish welfare and operational outcomes in salmon aquaculture.
